Skip to main content

Table 3 Antinociceptive activities

From: Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor

  ED 50(mg/kg, s.c.) (95% CL)
  HP a TF b PPQ c
Oxycodoned 1.37 (0.48-3.92) 0.94 (0.40-2.30) 0.38 (0.19-0.75)
14-OMC 1.02 (0.52-2.01) 0.80 (0.32-2.04) 0.22 (0.12-0.41)
1 d 0.50 (0.12-2.02) 1.88 (1.25-2.83) 0.18 (0.076-0.42)
2 d 0.15 (0.054-0.41) 0.12 (0.061-0.23) 0.026 (0.012-0.055)
3 d 0.25 (0.11-0.59) 0.21 (0.11-0.40) 0.11 (0.072-0.16)
4 1.30 (0.56-3.03) 1.34 (0.53-3.03) 0.18 (0.08-0.43)
5 0.080 (0.011-0.61) 0.040 (0.020-0.090) 0.0023 (0.0009-0.0060)
6 0.089 (0.037-0.21) 0.12 (0.070-0.20) 0.003 (0.0007-0.012)
  1. Antinociceptive potencies in mice after s.c. administration shown as ED50 values with 95% confidence limits (95% CL) (n = 6–10 mice per group). aHot-plate (HP) test. bTail-flick (TF) test. cPPQ abdominal stretching test. dData from [30].